Fundraising Fox
ReAlta Life Sciences
Norfolk, US · Founded 2017 · Delaware corporation · 1 known investors
Find your way into ReAlta Life Sciences
997 people in our graph share verified history with the ReAlta Life Sciences team — schools, employers, funds. One of them is your warm intro.
Justin Robenyunlockedknows David Marek · together at Axsome Therapeutics (overlapped)
×2knows the team · via WebMD
×2knows the team · via Publicis
×7knows the team · via The F Suite
ReAlta Life Sciences develops pegtarazimod, a drug candidate that modulates upstream inflammatory pathways (neutrophils and complement) and is in Phase 2 clinical trials for neonatal Hypoxic Ischemic Encephalopathy (HIE). The compound is positioned as a platform asset with potential applications across multiple inflammatory diseases.
Founders & leadership
ReAlta Life Sciences was founded in 2017 by Neel Krishna and Kenji Cunnion.
NK
Neel KrishnaCo-founder · Chief Scientific OfficerNeel Krishna is an Executive Officer at ReAlta Life Sciences, which develops pegtarazimod, a drug candidate in Phase 2 clinical trials for neonatal hypoxic ischemic encephalopathy that targets upstream inflammatory pathways.
JR
John RickmanChief Financial OfficerJohn Rickman served as Chief Financial Officer and led corporate development at business process outsourcing firms, where he executed mergers, acquisitions, and financing transactions while building organizational structure and implementing internal controls.
PM
Paolo MartiniChief Research & Development Officer2024–2026Paolo Martini is an Executive Officer at ReAlta Life Sciences with 18 years of experience in discovery research and molecular biology, including expertise in monogenic and multigenic rare diseases, hematologic malignancies, and fibrotic diseases, along with background in project management and pre-IND development.
DM
David MarekChief Executive Officer and Board Director2024–2025David Marek is an Executive Officer and Director at ReAlta Life Sciences, a biopharmaceutical company developing pegtarazimod for inflammatory diseases including neonatal Hypoxic Ischemic Encephalopathy. He has held leadership roles across multiple therapeutic areas in biopharma, healthcare media, data, and advertising companies.
UT
Ulrich ThienelNamed on SEC filing
JN
Jerry NadlerNamed on SEC filing
JH
John HardingNamed on SEC filing
Board
AM
Andrew MillerBoard director
MA
Mert AktarBoard director
TK
Thomas Kerry McCarterManaging Director
LW
Lewis WilliamsBoard director
Investors · 1
Also in the syndicate · 1
Massinvestor, Inc.
Funding
SEC filings, press & company announcements$134.3M disclosed across 6 of 8 rounds · 2018–2026
- $40MraisedApr 2026 · 4 sources
Massinvestor, Inc.
Source ↗
▶$29.9MraisedMay 2025 · 149 investors · BiotechnologyRule 506(b)
▶$29.9MraisedMay 2025 · 149 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John RickmanExecutive Officer
- Andrew MillerDirector
- Neel KrishnaExecutive Officer
- Lewis WilliamsDirector
- Frank GadamsDirector
- Kenji CunnionExecutive Officer
- Paolo MartiniExecutive Officer
- Mert AktarDirector
- Edward Heidt, Jr.Director
- Laurie GlimcherDirector
- Christi ShawDirector
- David MarekExecutive Officer, Director
- Emma ReeveDirector
- Offering amount
- $30M
- Amount sold
- $29.9M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedMay 2025 · 109 investors · BiotechnologyRule 506(b)
▶$25MraisedMay 2025 · 109 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Laurie GlimcherDirector
- David MarekExecutive Officer, Director
- Edward Heidt, Jr.Director
- Lewis WilliamsDirector
- Andrew MillerDirector
- Kenji CunnionExecutive Officer
- John RickmanExecutive Officer
- Frank GadamsDirector
- Paolo MartiniExecutive Officer
- Emma ReeveDirector
- Mert AktarDirector
- Christi ShawDirector
- Neel KrishnaExecutive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedMay 2025 · 85 investors · BiotechnologyRule 506(b)
▶$12MraisedMay 2025 · 85 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew MillerDirector
- Paolo MartiniExecutive Officer
- Frank GadamsDirector
- Laurie GlimcherDirector
- John RickmanExecutive Officer
- David MarekExecutive Officer, Director
- Mert AktarDirector
- Neel KrishnaExecutive Officer
- Lewis WilliamsDirector
- Kenji CunnionExecutive Officer
- Christi ShawDirector
- Emma ReeveDirector
- Edward Heidt, Jr.Director
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22.5MraisedSep 2023 · 92 investors · BiotechnologyRule 506(b)
▶$22.5MraisedSep 2023 · 92 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward Heidt, Jr.Director
- Deborah GeraghtyDirector
- Jonathan ZalevskyDirector
- Christine NeikirkDirector
- John RickmanExecutive Officer
- Neel KrishnaExecutive Officer
- Azmi NabulsiDirector
- Kathryn AbshireExecutive Officer
- Barry StrasnickDirector
- Ulrich ThienelExecutive Officer, Director
- Frank GadamsDirector
- Kenji CunnionExecutive Officer, Director
- Offering amount
- $22.5M
- Amount sold
- $22.5M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MofferedFeb 2020 · PharmaceuticalsRule 506(b)
▶$2MofferedFeb 2020 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Edward Heidt, Jr.Executive Officer, Director
- Thomas Kerry McCarterExecutive Officer
- Jonathan ZalevskyDirector
- Azmi NabulsiDirector
- Deborah GeraghtyDirector
- Frank GadamsDirector
- Barry StrasnickDirector
- Christine NeikirkDirector
- John RickmanExecutive Officer
- Neel KrishnaExecutive Officer
- Ulrich ThienelExecutive Officer, Director
- Kenji CunnionExecutive Officer, Director
- Offering amount
- $2M
- Minimum investment
- $75K
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$12MofferedOct 2019 · PharmaceuticalsRule 506(b)
▶$12MofferedOct 2019 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ulrich ThienelExecutive Officer, Director
- Kenji CunnionExecutive Officer, Director
- Neel KrishnaExecutive Officer
- John HardingExecutive Officer, Director
- Barry StrasnickDirector
- Edward Heidt, Jr.Director
- Frank GadamsDirector
- Thomas Kerry McCarterExecutive Officer
- John RickmanExecutive Officer
- Offering amount
- $12M
- Proceeds to insiders
- $619K
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$4.8MraisedSep 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$4.8MraisedSep 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Edward Heidt, Jr.Director
- Ulrich ThienelDirector
- Jerry NadlerDirector
- Neel KrishnaExecutive Officer
- Thomas Kerry McCarterExecutive Officer
- John HardingDirector
- Kenji CunnionExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $4.8M
- Proceeds to insiders
- $14K
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through ReAlta Life Sciences went on to found or lead other companies.
Competitors · 1
by search overlap
Companies competing with ReAlta Life Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.5M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does ReAlta Life Sciences do?
- ReAlta Life Sciences develops pegtarazimod, a drug candidate that modulates upstream inflammatory pathways (neutrophils and complement) and is in Phase 2 clinical trials for neonatal Hypoxic Ischemic Encephalopathy (HIE). The compound is positioned as a platform asset with potential applications across multiple inflammatory diseases.
- Who founded ReAlta Life Sciences?
- ReAlta Life Sciences was founded by Neel Krishna, Kenji Cunnion in 2017.
- How much funding has ReAlta Life Sciences raised?
- ReAlta Life Sciences has disclosed $134.3M raised across 6 of its 8 known rounds.
- Where is ReAlta Life Sciences headquartered?
- ReAlta Life Sciences is headquartered in Norfolk, US.